Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
1.
Allergol Immunopathol (Madr) ; 32(6): 352-60, 2004.
Article in English | MEDLINE | ID: mdl-15617663

ABSTRACT

UNLABELLED: The adverse reactions that may occur during a surgical intervention are of concern to anesthesiologists and allergists due to the civil responsibility they entail and the increased demand for healthcare in allergology units. The aim of the present study was to determine the prevalence of adverse reactions in our setting (Island of Lanzarote) and modifications to immune response mediators using three types of representative myorelaxants (succinylcholine, cisatracurium and vecuronium) in order to predict and prevent adverse reactions. MATERIAL AND METHODS: We performed a prospective, cross sectional, observational study in a population of 201 patients scheduled to undergo surgery in the Surgery Department of the Lanzarote General Hospital from October 1998. Three groups were retrospectively selected: vecuronium (73 patients), cisatracurium (80 patients), and succinylcholine (48 patients). Blood was extracted from all patients before and after the intervention and the following in vitro variables were evaluated: histaminemia, eosinophil cationic protein, tryptase, IgE to latex, CD4/CD8 fractions, total lymphocytes, total IgE, C3 and C4, and also the histaminuria. CONCLUSIONS: The mean age of the patients was 41 years with a predominance of women. Sixty percent had not previously undergone surgery. The mean operating time was 2 hours. Digestive surgery accounted for the greatest number of interventions (38.8 %) and most of the patients had no personal history of atopy (91.5 %). The greatest number of perioperative reactions was produced by cisatracurium (38.8 %), followed by succinylcholine (27.4 %) and vecuronium (20 %). The reactions observed were immediate type 1 and 2 reactions. All reactions were reversible without sequelae. Histaminuria levels were significantly decreased in the cisatracurium group. Histaminemia and eosinophil cationic protein showed no significant changes in any of the three groups. Tryptase concentrations in blood did not increase in the postoperative period in any of the three groups. On the contrary, concentrations were significantly lower than basal values. In the vecuronium and succinylcholine groups, CD4/CD8 fractions decreased in the postoperative period. Total lymphocytes decreased in all three groups. Total IgE tended to decrease in the cisatracurium and succinylcholine groups. IgE to latex was negative in the three groups. Specific IgE to succinylcholine was unmodified. C3 complement fraction was unmodified in all three groups and C4 fraction was reduced in the vecuronium group. In our setting and in our patients, the three myorelaxants produced immunosuppression of immune response mediators. The present study confirms that tests for allergy to myorelaxants are not indicated in the preoperative period.


Subject(s)
Anesthesia, General , Atracurium/analogs & derivatives , Atracurium/adverse effects , Drug Hypersensitivity/etiology , Intraoperative Complications/chemically induced , Neuromuscular Depolarizing Agents/adverse effects , Neuromuscular Nondepolarizing Agents/adverse effects , Succinylcholine/adverse effects , Vecuronium Bromide/adverse effects , Adolescent , Adult , Aged , CD4-CD8 Ratio , Complement C3/analysis , Complement C4/analysis , Cross-Sectional Studies , Drug Hypersensitivity/epidemiology , Drug Hypersensitivity/metabolism , Drug Hypersensitivity/prevention & control , Eosinophil Cationic Protein/analysis , Female , Histamine/blood , Histamine/urine , Humans , Immunoglobulin E/blood , Intraoperative Complications/epidemiology , Intraoperative Complications/prevention & control , Leukocyte Count , Lymphocyte Subsets/drug effects , Male , Mast Cells/enzymology , Middle Aged , Preoperative Care , Prevalence , Prospective Studies , Serine Endopeptidases/analysis , Tryptases
2.
Allergol. immunopatol ; 32(6): 352-360, nov. 2004.
Article in En | IBECS | ID: ibc-36818

ABSTRACT

The adverse reactions that may occur during a surgical intervention are of concern to anesthesiologists and allergists due to the civil responsibility they entail and the increased demand for healthcare in allergology units. The aim of the present study was to determine the prevalence of adverse reactions in our setting (Island of Lanzarote) and modifications to immune response mediators using three types of representative myorelaxants (succinylcholine, cisatracurium and vecuronium) in order to predict and prevent adverse reactions. Material and methods: We performed a prospective, cross sectional, observational study in a population of 201 patients scheduled to undergo surgery in the Surgery Department of the Lanzarote General Hospital from October 1998. Three groups were retrospectively selected: vecuronium (73 patients), cisatracurium (80 patients), and succinylcholine (48 patients). Blood was extracted from all patients before and after the intervention and the following in vitro variables were evaluated: histaminemia, eosinophil cationic protein, tryptase, IgE to latex, CD4/CD8 fractions, total lymphocytes, total IgE, C3 and C4, and also the histaminuria. Conclusions: The mean age of the patients was 41 years with a predominance of women. Sixty percent had not previously undergone surgery. The mean operating time was 2 hours. Digestive surgery accounted for the greatest number of interventions (38.8 %) and most of the patients had no personal history of atopy (91.5 %). The greatest number of perioperative reactions was produced by cisatracurium (38.8 %), followed by succinylcholine (27.4 %) and vecuronium (20 %). The reactions observed were immediate type 1 and 2 reactions. All reactions were reversible without sequelae. Histaminuria levels were significantly decreased in the cisatracurium group. Histaminemia and eosinophil cationic protein showed no significant changes in any of the three groups. Tryptase concentrations in blood did not increase in the postoperative period in any of the three groups. On the contrary, concentrations were significantly lower than basal values. In the vecuronium and succinylcholine groups, CD4/CD8 fractions decreased in the postoperative period. Total lymphocytes decreased in all three groups. Total IgE tended to decrease in the cisatracurium and succinylcholine groups. IgE to latex was negative in the three groups. Specific IgE to succinylcholine was unmodified. C3 complement fraction was unmodified in all three groups and C4 fraction was reduced in the vecuronium group. In our setting and in our patients, the three myorelaxants produced immunosuppression of immune response mediators. The present study confirms that tests for allergy to myorelaxants are not indicated in the preoperative period (AU)


Las reacciones adversas que puedan ocurrir durante una intervención quirúrgica preocupan a los anestesistas y a los alergólogos por la responsabilidad civil que conlleva y el aumento de la demanda asistencial en las Unidades de Alergología. El propósito del presente trabajo ha sido valorar la prevalencia de reacciones adversas en nuestro medio (Isla de Lanzarote), y las modificaciones de los mediadores de la respuesta inmune utilizando tres tipos de miorrelajantes respresentativos como son las succinilcolina, el cisatracurio y el vecuronio, con fines predictivos y preventivos. Material y métodos: Ha sido un diseño prospectivo, trasversal, observacional, en una población de 201 pacientes programados por el Servicio de Cirugía desde octubre de 1998, en el Hospital General de Lanzarote. Se separaron en tres grupos, anestesiados con Vecuronio (73 pacientes), Cisatracurio (80 pacientes), Succinilcolina (48 pacientes). A todos ellos se les hacía una extracción sanguínea pre y post-operatoria, valorándose los parámetros siguientes: Histaminemia, proteína catiónica del eosinófilo, triptasa, IgE al látex, fracciones CD4/CD8, linfocitos totales, IgE total, C3 y C4 y además la histaminuria. Conclusiones: Edad media de los pacientes, 41 años, predominio del sexo femenino. El 60 por ciento no habían tenido intervenciones previas. Tiempo promedio de intervención: 2 dos horas. La cirugía digestiva supuso el mayor número de intervenciones (38,8 por ciento) y el 91,5 por ciento de los pacientes no tenían antecedentes personales de atopia. El mayor número de reacciones perioperatorias se produjeron por el Cisatracurio (38,8 por ciento), seguida de Succinilcolina (27,4 por ciento) y en tercer lugar el Vecuronio (20 por ciento). Las reacciones observadas fueron tipo 1 y 2 de aparición inmediata y en su totalidad reversible sin secuelas. Los niveles de histaminuria descendieron significativamente en el grupo del Cisatracurio. Ni la histaminemia ni la proteína catiónica de los eosinófilos, se modificaron significativamente en ninguno de los tres grupos. La triptasa en sangre no aumentó en el postoperatario en ninguno de los grupos. Por el contrario hay una disminución significativa con respecto a sus valores basales. La relación CD4, CD8 se modificó en los grupos del Vecuronio y Succinilcolina, disminuyendo en la situación postquirúrigica. Los linfocitos totales disminuyen en los tres grupos. La IgE total tiende a bajar en los grupos del Cisatracurio y Succinilcolina. La IgE al látex fue negativa en los tres grupos. La IgE específica a a la Succinilcolina no se modificó. La fracción C3 del complemento no se modifica en ninguno de los tres grupos, y la fracción C4 se reduce en el grupo del Vecuronio. En nuestro medio (Lanzarote) y en nuestros pacientes, los tres miorrelajantes produjeron una inmunosupresión de los mediadores de la respuesta inmune. El presente estudio corrobora la no indicación de pruebas alérgicas a miorrelajantes en pacientes en situación preoperatoria (AU)


Subject(s)
Male , Middle Aged , Humans , Aged , Adult , Female , Adolescent , Anesthesia, General , Serine Endopeptidases , Leukocyte Count , Lymphocyte Subsets , Mast Cells , Neuromuscular Nondepolarizing Agents , Preoperative Care , Vecuronium Bromide , Prospective Studies , Succinylcholine , Immunoglobulin E , Prevalence , Intraoperative Complications , Atracurium , Cross-Sectional Studies , Drug Hypersensitivity , Histamine , CD4-CD8 Ratio , Blood Proteins , Neuromuscular Depolarizing Agents , Complement C3 , Complement C4
3.
Allergol Immunopathol (Madr) ; 26(4): 195-8, 1998.
Article in English | MEDLINE | ID: mdl-9816408

ABSTRACT

Three cases of clinical angioedema are reported in which the etiopathogenetic involvement of qualitative and quantitative complement disorders was demonstrated. The first patient had a functional deficit in C1 inhibitor, the second had a decrease in CH50, and the third, a reduction in the C1q, C3, and C4 fractions. The cases are interesting because of occasional difficulties in the causal diagnosis, the severity of the symptoms, which can include laryngeal edema, and, finally, the favorable outcome achieved with correct medication, which did not include antihistamines or steroids. The clinical picture of hereditary angioedema is characterized by the familial occurrence of the process, although this apparently was absent in these cases. Two patients experienced laryngeal edema and none had abdominal manifestations. The treatment of choice for angioedema of these characteristics is antifibrinolytic agents, which achieve good results in 70% of the patients. Epsilon-aminocaproic acid and tranexamic acid inhibit the formation of plasmin and fragments of the Hageman factor, thus inhibiting kallikrein and bradykinin production. The androgens danazol and stanazolol have been used since the 1970s, and stanazolol proved to be very effective in two of our patients.


Subject(s)
Angioedema/etiology , Complement C1 Inactivator Proteins/deficiency , Complement System Proteins/deficiency , Adult , Aminocaproic Acid/therapeutic use , Angioedema/drug therapy , Angioedema/genetics , Antifibrinolytic Agents/therapeutic use , Complement C1 Inactivator Proteins/genetics , Complement C1 Inactivator Proteins/therapeutic use , Complement C1q/deficiency , Complement C3/deficiency , Complement C4/deficiency , Complement System Proteins/genetics , Danazol/therapeutic use , Female , Humans , Laryngeal Edema/drug therapy , Laryngeal Edema/etiology , Male , Middle Aged , Stanozolol/therapeutic use , Tranexamic Acid/therapeutic use
4.
Allergol Immunopathol (Madr) ; 23(3): 105-10, 1995.
Article in Spanish | MEDLINE | ID: mdl-7572538

ABSTRACT

In the present study we assessed the prevalence of sensitizations to Blomia in our environment. Perennial climatological conditions in the Canarian Islands facilitates the habitat to mites. The Blomia is found in tropical and subtropical homes of Europe, USA and Asia like the Dermatophagoides. We have designed a transversal and prospective study on 100 patients who consulted our Unit for the first time. A Prick-test for the common allergens, including Blomia Kulagini, and in vitro determination of total and specific IgE to Dermatophagoides Pteronyssinus and Farinae, was performed in those patients showing the same or higher levels than class 3 CAP System RAST-Fesa against Blomia Tropicalis. Results achieved in our environment and our patients are the following: 1. Prevalence of sensitizations to BK in patients who consult for the first time is 50%. 2. The specific IgE immunologic response to BK is 56% (45 patients). 3. Scarce correlation in the papule areas and specific IgE levels between BT and DTP (p = 0.22020); BT and DFA (p = 0.09063). Table VI. Fig. I and II. 4. These results and previous studies of allergenization suggest poor crossed reactivity between Blomia and Dermatophagoides. 5. We think that Blomia is a new etilogic agent of the allergic respiratory disorders in our environment and therefore it should be included in the standard set of allergens from a diagnostic and therapeutical point of view. We keep studying its identification and count in dust samples from our homes, as well as the crossed reactivity, by RAST inhibition, with other acari.


Subject(s)
Allergens/immunology , Hypersensitivity/epidemiology , Mites/immunology , Adolescent , Adult , Animals , Child , Child, Preschool , Cross-Sectional Studies , Female , Humans , Hypersensitivity/immunology , Male , Prevalence , Prospective Studies , Spain/epidemiology
5.
Allergol Immunopathol (Madr) ; 17(6): 323-9, 1989.
Article in English | MEDLINE | ID: mdl-2635834

ABSTRACT

There is discrepancy of criteria regarding the clinical immunological efficacy of allergenic extracts, administered by oral way, for the control of allergic symptoms of the respiratory airways. The predominant mono-sensitization to D. pteronyssinus and the early development of allergic respiratory symptoms in our medium motivated us to evaluate the clinical-immunological efficacy of oral immunotherapy in children with bronchial asthma. Twenty-eight patients affected with extrinsic bronchial asthma to D. pteronyssinus were included in our study; their average age was 27.93 months (range between 18-42 months) and the SD (standard deviation), 5.46. For the reception of oral and subcutaneous vaccines, made-up of 100% D. pteronyssinus, the patients were divided into two groups of 14 children each. The clinical immunological evaluation was realized in basal conditions, 6 and 12 months after the initiation of both vaccines. IgE and seric IgG4 against D. pteronyssinus was quantified through RAST. The results obtained were as follows: 1. Subcutaneous immunotherapy (SI) was seen to be more effective than oral immunotherapy (OI), throughout the 12 months of the study. 2. In both vaccines, the IgE against D. pteronyssinus did not undergo any statistically significant changes (p less than 0.766 and p less than 0.246). 3. IgG4 against D. pteronyssinus increased more with subcutaneous than with oral therapy. There were statistically significant differences for both kinds of therapy at 6 and 12 months, the difference between basal and 12 months being p less than 0.001 and p less than 0.020, for subcutaneous and oral therapy respectively.(ABSTRACT TRUNCATED AT 250 WORDS)


Subject(s)
Allergens/therapeutic use , Asthma/therapy , Desensitization, Immunologic/methods , Administration, Oral , Allergens/administration & dosage , Animals , Antigens, Dermatophagoides , Asthma/etiology , Asthma/immunology , Child, Preschool , Dust , Humans , Immunoglobulin E/analysis , Immunoglobulin G/analysis , Infant , Injections, Subcutaneous , Mites/immunology
SELECTION OF CITATIONS
SEARCH DETAIL
...